Inhibin is a polypeptide hormone produced by the granulosa cells of the ovary, and is present in body as dimers of vanous sies each compnsng an a-and a-subunit. Free forms of the a-subunit also circulate, and the presently available radioimmunoassay (Monash asy) cannot distinguish these from biologicaly active dimeric inhibin. Recently we described a new two-site enzyme immunoassay able for the first time to measure the kvels of dimeric inhibin throughout the human menstrual cycle. The sensitivity limit of this assay is 2 pg ml-' in human serum with cross-reactivity against activin of 0.05%. The normal range of inhibin in post-menopausal women is <5 pg mll, in pre-menopausal women 2 -80 pg ml (2 -10 pg ml iin the follicular phase, 40 -80 pg ml-' in the luteal phase). This assay was used to determine inhibin levels in sera from 15 (five pre-menopausal and ten post-menopausal) patients with granulosa cell tumours of the ovary. It was raised in a pre-menopausal patient preoperatively (261 pg ml -), in six post-menopausal patients (32, 43, 54, 66, 24 
The incidence of ovarian cancer in England and Wales is approximately 5000 new cases per annum. It is the fourth commonest cancer in women and the leading cause of death from gynaecological cancer. In a recent meta-analysis of all randomised clinical trials in ovarian cancer after surgery, the median survival was 30% at 5 years (Advanced Ovanan Cancer Triallst's Group, 1991) . The poor survival is due to patients presenting at an advanced stage of the disease, and consequently screening for early detection has been intensively investigated. There are still no reliable screening procedures which detect ovarian cancer consistently. Ovarian cancer itself comprises epithelial ovarian cancer (90%) and sex cord-stromal tumours (10%). Biochemical markers for epithelial ovarian cancer include CA-125, which is particularly useful in serous adenocarcinomas, in which it is elevated (80% of cases) and has been found to be useful as a prognostic indicator (Jacobs and Bast, 1989) . In stromal tumours, particularly granulosa cell-tumours, oestradiol and more recently inhibin have been reported as useful markers reflecting presence of disease (Lappohn et al., 1989) . A recent report demonstrated that inhibin is also elevated in postmenopausal women with mucinous tumours of the ovary, which normalise after surgery (Healy et al., 1993) .
Inhibin is a polypeptide hormone produced by the granulosa cells of the ovary and which inhibits follicle-stimulating hormone (FSH) secretion by the anterior pituitary gland. Although its existence was first hypothesised in 1932 (McCullagh, 1932) it was not until 1986 that the measurement of serum inhibin levels became possible (Tsonis et al., 1986) . A radioimmunoassay (RIA) to measure inhibin levels throughout the normal female menstrual cycle, commonly called the Monash assay (McLachlan et al., 1987) , was reported in 1987. Inhibin is a glycoprotein made of two subunits; an a-subunit and a a-subunit, giving rise to two generic forms (A and B) of apparently identical biological activity. In addition, in both serum and follicular fluid there exist other related polypeptides: activin, follistatin and free £-subunits. Current radioimmunoassays are unable to distinguish between dimeric (biologically active) forms of inhibin and free (biologically inactive) a-subunits (Schneyer et al., 1990) . There is a widely-recognised need for a convenient and sensitive immunoassay which can detect the dimeric form of inhibin and distinguish it from free inactive forms of the a-subunit, which may occur in greater amounts in follicular fluid and serum.
The recent development of a new sensitive two-site immunoassay using monoclonal antibodies to the a-subunit and the a-A-subunit of inhibin, developed by synthetic peptide immunisations, has been instrumental in evaluating levels of dimeric inhibin in serum (Groome and O'Brien, 1993; Groome et al., 1994) . The assay can detect as litle as 2 pg ml-1 of dimeric inhibin in human serum and plasma (Groome et al., 1994) and has now been used in measuring levels in sera of patients with both granulosa cell tumours of the ovary and epithelial ovarian cancer. This assay specifically measures dimeric biologically active inhibin with high sensitivity in both pre-and post-menopausal women. The results confirm the earlier report that inhibin is a valuable tumour marker in granulosa cell tumours, and at least some of the inhibin secreted is the biologically active dimeric form. 
Assays
Inhibin The technique for the two-site enzyme linked immunosorbent assay has been described previously ( Figure  1 ) (Groome and O'Brien, 1993; Groome et al., 1994) . Briefly, the assay is based on the use of an immobilised monoclonal antibody (E4) to the n-A-subunit as capture antibody. The Fab fraction of a mouse monoclonal antibody to the Nterminal portion of the 20 kDa ca-subunit (RI) conjugated to alkaline phospatase is used for detection. The monoclonal antibody E4 is coupled covalently to a microtitre plate (Avidplate-HZ) through the carbohydrate residues on the Fc of the anitbody. This antibody captures dimeric inhibin from the sample or standards via the a-A-subunit ignoring free a-subunits. After a wash, the Fab/alkaline phosphatase conjugate is added and binds to the previously captured dimeric inhibin. Following a final wash, the alkaline phosphatase is detected by a sensitive amplified enzyme assay (AMPAK, Dako Diagnostics). The use of hydrazide-treated plates ensures full recovery of inhibin from serum and plasma.
Samples and standards were pretreated with 1% hydrogen peroxide for 30 min before the assay, to enhance detection of inhibin by E4 (Groome et al., 1994) . Recombinant inhibin A was used as the standard. The sensitivity limit of this assay is 2 pg ml-' in human serum with cross-reactivity against activin of 0.05%.
Other hormones Follicle-stimulating hormone (FSH) and luteinising hormone levels were measured by radioimmunoassay using a standard kit (Ferguson et al., 1982; Beastall et al., 1987) . The normal laboratory range for FSH is 0.5-8.0 IU I`in pre-menopausal and above 30 IU 1-1 in post-menopausal women. Oestradiol levels were measured using a commercially available kit by radioimmunoassay (Gamma B-Direct Oestradiol Kit, Immunodiagnostic Systems). The normal laboratory range is 75-300 pmol 1`in premenopausal and less than 40 pmol 1-' in post-menopausal women.
CA-125 CA-125 levels in sera were measured using a commercially available kit by enzyme immunoassay (Cobas Core, CA-125 II EIA). The normal value is less than 36 U ml-'. Normal menstrual c) cle After validation the assay was used to evaluate the levels in sera from normal pre-menopausal and post-menopausal women (Groome et al., 1994) . In post-menopausal women, dimeric inhibin was usually undetectable and never higher than 5 pg ml-'. The levels of inhibin and the correlation with FSH through a normal menstrual cycle of a premenopausal woman are shown in Figure 2 . The inhibin level is low in the early follicular phase [3.4 pg ml-', confidence interval (CI) 2.2-5.0 pg ml-'], increasing in the mid-follicular phase (7.2 pgml-' CI. 5.9-8.8pgml-') and to a maximum in the mid-luteal phase (65.6 pg ml-' CI 53.1-81.1 pgml-' ). The concentration during the menstrual cycle varied 20-fold with this assay. Similar results were obtained by daily estimation of inhibin levels in normal women (Groome et al., 1994) .
Granulosa cell twnours Sera at different time points from five premenopausal and ten post-menopausal patients with granulosa cell tumours were assessed for inhibin concentrations. The levels of inhibin in one premenopausal patient (Table 1 , patient 1; Figure 3 ) were high preoperatively and fell within the normal range following surgery. It was also elevated in a patient at relapse (Table I , patient 4) and associated with a low FSH level. In two patients the levels were normal, while in another who was in clinical and radiological remission the levels were elevated above normal range. This patient was on oestrogen replacement therapy. In post-menopausal patients, the levels of inhibin were elevated in six with active disease. The levels of FSH were low when measured in the same serum sample. In four patients whose disease was in remission inhibin was in the normal range (Table II (Table III) . The level was normal in all patients with serous adenocarcinoma preoperatively or at relapse. It was elevated above the normal post-menopausal range (<5 pg ml-' ) in eight patients preoperatively and in one patient at relapse. The FSH levels, however, did not always correlate with inhibin levels. CA-125 levels were more accurately reflective of active disease than inhibin. Serial levels from one patient with endometrioid adenocarcinoma are shown in Figure 6 . There is a 20-fold rise in this assay compared with only a 4-fold increase observed with the Monash assay (McLachlan et al., 1987; Groome et al., 1994) . Granulosa cells tumours account for 2% of all ovarian tumours. Although not considered aggressive tumours, the long-term survival is poor in patients with extraovarian spread, which is often late. The 20 year actuarial survival rate is 34% (Dempster et al., 1987 vation on a few natients. although the nature of inhibin being measured was uncertain owing to the limitations of the Monash assay. It was inferred that functional inhibin was secreted by these tumours as it was associated with low FSH levels, particularly in post-menopausal patients. The present report is the first to demonstrate that functional dimeric inhibin is secreted by granulosa cell tumours. The elevated inhibin levels detected at presentation or at relapse correlate with low FSH levels at the same time. Serial measurement of inhibin levels in patients from whom sera were available demonstrated a rise before the development of clinically overt disease and a fall with subsequent therapy. In postmenopausal patients the low levels of inhibin normally detected (<2 pg ml-'), make it easy to detect recurrence. In premenopausal patients in whom an ovary is conserved, inhibin levels will vary with the menstrual cycle. The normal level in the early follicular phase, immediately after menstruation is less than 5 pg ml-'. It is therefore important to interpret inhibin levels in relation to the menstrual cycle. Follow-up serum samples in premenopausal women are best taken at or immediately after menstruation when the basal inhibin levels are low. The patient (5, Table 1) in whom inhibin levels were elevated while in radiological remission was on oestrogen replacement therapy. Serial samples have not shown a progressive increase in levels. The oestradiol level in patients with active disease was normal in all but one. This, in association with elevated inhibin and low FSH levels, suggests that it may be inhibin that is providing the feedback control of FSH. Indirect evidence in support of this is provided by the observation of elevated FSH levels in patients with gonadal failure on oestrogen replacement therapy (Cameron et al., 1989) . Measurement of inhibin levels in such patients would be valuable in further understanding of the relative roles of inhibin and ovarian steroids in the control of FSH secretion.
The results in malignant epithelial ovarian tumours were quite different. Inhibin was detected above the normal range in eight patients preoperatively and in one at relapse. The levels were slightly elevated; one patient alone had a level greater than 50pgml-', and this was associated with low FSH levels (Figure 6 ). Three of the nine patients with elevated levels had endometrioid adenocarcinoma, while another three had mucinous adenocarcinoma. The observation that inhibin levels are elevated in mucinous adenocarcinoma (Healy et al., 1993) could not be confirmed confidently because there were only three such patients in this study. However, no patient with serous adenocarcinoma had abnormal levels. This study confirms that dimeric inhibin is being measured in epithelial ovarian cancer, while the earlier report measured inhibin-like immunoreactivity (Healy et al., 1993) . A larger prospective study needs to be performed to evaluate the role of inhibin as a tumour marker in epithelial ovarian cancer and to identify the various molecular forms circulating in the serum of such patients. There are two possible explanations for secretion of functional inhibin by epithelial tumours. Firstly, it may reflect a stromal response to the tumour. Secondly, it may reflect the intrinsic ability of the surface epithelium of the ovary to secrete inhibin, as the embryological origin is shared with the rest of the genital tissue.
The development of tumour markers has been useful in prognostic and therapeutic decision-making. This is exemplified by the use of m-fetoprotein and -chorionic gonadotrophin in the management of testicular cancer. The same markers are useful in the management of yolk sac tumours, teratomas and dysgerminomas of the ovary. In patients with granulosa cell tumours, recurrences are often late, requiring long-term follow-up. This reliable enzyme-linked immunosorbent assay for dimeric inhibin should be more valuable than oestradiol in monitoring for recurrence during follow-up. Detailed evaluation of the specificity and sensitivity of inhibin as a tumour marker in granulosa cell tumours is ongoing and would confirm the above preliminary observations. Further study of the inhibin molecular forms secreted by epithelial ovarian tumours is required before any conclusion can be drawn about its potential as tumour marker in such tumours.
